FDA Grants Breakthrough Therapy Designation to Novartis Ianalumab for Sjögren’s Disease
I'm PortAI, I can summarize articles.
Novartis AG has received Breakthrough Therapy designation from the FDA for ianalumab, aimed at treating Sjögren’s disease. This designation is based on phase III trial results indicating its potential to meet significant unmet medical needs. Novartis plans to seek global regulatory approval for ianalumab starting in early 2026, which could make it the first targeted treatment for this autoimmune condition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments